# Bivision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bivision

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.bivisionpharma.com
- Total disclosed funding: $101M
- Latest round: Series B (May 18, 2026)
- Investors on record: 17

## About

Based in Shanghai, China, and founded in 2021, Bivision is a biopharmaceutical developer focused on developing next-generation targeted radionuclide therapies that are image-guided and integrate diagnosis and treatment. The company's co-founder, Haihua Yu, is a PhD in Medicinal Chemistry, Fudan University. In December 2023, its drug, JH02, completed Phase I clinical trials. In July 2024, Bivision closed a series A funding co-led by Golden China Fund and Huajin Dadao Investment. In January 2025, Bivision raised approximately CNY 100 million in series A+ funding from new investors Trinity Innovation Fund and China International Capital Corporation, with participation from returning investor Gaorong Ventures.

Bivision has three major technology platforms which are targeted ligand screening, radioactive drug conjugation, and drug clinical transformation. The company's technology platforms can be used for ligand screening, modulation of coupling factors (J-Linker) and clinical transformation. Its product pipeline includes JH002, JH003, JH004, N001 and N002. The drugs can be used to treat cancer.

The company generates revenue by developing drugs that can be used to treat cancer.

The company will use the funds for the clinical advancement of JH02, IND application and clinical development of JH04, as well as subsequent preclinical studies and IIT studies of multiple global innovative pipelines. The company will also continue to promote its global layout, including the launch of overseas clinical trials and cooperative development of overseas rights and interests of projects.

## Funding rounds

- Series B, May 18, 2026, $59M — IDG Capital, Richfields Capital, Gaorong Ventures, Sealand Innovation, Jinkong Qiyuan Capital, Pudong Venture Capital, Zhangjiang Science & Technology Venture Capital, Shanghai Songqing Private Equity Fund Management
- Series A, Jan 17, 2025, $14M — China International Capital Corporation, Gaorong Ventures, Trinity Innovation Fund
- Series A, Jul 27, 2024, $14M — Golden China Fund, Gaorong Ventures, Tigermed, Elikon Venture, Huajin Dadao Investment
- Angel, Aug 22, 2022, $15M — Kaitai Capital, Gaorong Ventures, Virtus Inspire Ventures, Elikon Venture
- Seed, Sep 8, 2021 — Kaitai Capital, Yijing Investment

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Seed, Angel
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Seed
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Angel, Series A, Series B
- Virtus Inspire Ventures (https://capitalatlas.ai/funds/virtus-inspire-ventures) — Angel
- Elikon Venture (https://capitalatlas.ai/funds/elikon-venture) — Angel, Series A
- Golden China Fund (https://capitalatlas.ai/funds/golden-china-fund) — Series A
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A
- Huajin Dadao Investment — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series A
- Trinity Innovation Fund (https://capitalatlas.ai/funds/trinity-innovation-fund) — Series A
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B
- Richfields Capital (https://capitalatlas.ai/funds/richfields-capital) — Series B
- Sealand Innovation (https://capitalatlas.ai/funds/sealand-innovation) — Series B
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series B
- Pudong Venture Capital (https://capitalatlas.ai/funds/pudong-venture-capital) — Series B
- Zhangjiang Science & Technology Venture Capital (https://capitalatlas.ai/funds/zhangjiang-science-technology-venture-capital) — Series B
- Shanghai Songqing Private Equity Fund Management — Series B